EUCTR2020-001263-85-RO进行中（未招募）1 期
A randomized, double-blind, placebo-controlled clinical trial of once-daily inhaled molgramostim nebulizer solution in adult subjects with autoimmune pulmonary alveolar proteinosis (aPAP). - IMPALA-2
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- Savara ApS
- 入组人数
- 160
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Subject must be =18 years of age, at the time of signing the informed consent. Specific for Japan; Subject must be =20 years of age, at the time of signing the informed consent.
- •2. A serum anti-GM-CSF autoantibody test result confirming autoimmune PAP.
- •3. History of PAP, based on examination of a lung biopsy, bronchoalveolar lavage (BAL) cytology, or a high-resolution computed tomogram (HRCT) of the chest.
- •4. DLCO 70% predicted or lower at the Screening and Baseline visits.
- •5. Change in % predicted DLCO of <15% points during the screening period.
- •6. Demonstrated functional impairment in the treadmill exercise test (defined as a peak MET =8).
- •7. Willing and able to come off supplemental oxygen use prior to and during the treadmill exercise test, the DLCO assessment, and the arterial blood gas sampling.
- •8. Resting SpO2 >85% during 15 minutes without use of supplemental oxygen at the Screening visits.
- •9. Male or female
- •10. Contraceptive use by men or women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.
- •a. Male subjects: Males agreeing to use condoms during and until 30 days after last dose of trial treatment, or males having a female partner who is using adequate contraception as described below.
- •b. Female subjects: Females who have been post-menopausal for >1 year, or females of childbearing potential after a confirmed menstrual period using a highly efficient method of contraception (i.e. a method with <1% failure rate such as combined hormonal contraception, progesterone-only hormonal contraception, intrauterine device, intrauterine hormone-releasing system, bilateral tubal occlusion, vasectomized partner, sexual abstinence*), during and until 30 days after last dose of trial treatment. Females of childbearing potential must have a negative serum pregnancy test at Screening (Visit 1) and a negative urine pregnancy test at baseline (Visit 3) and must not be lactating.
- •*Sexual abstinence is considered a highly effective method only if defined as refraining from heterosexual intercourse during the entire period of risk associated with the trial treatments. The reliability of sexual abstinence needs to be evaluated in relation to the duration of the clinical trial and the preferred and usual lifestyle of the subject.
- •11. Capable of giving signed informed consent as described in Appendix 1 which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol.
- •12. Willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other trial procedures specified in the protocol as judged by the Investigator.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 140
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 20
排除标准
- •1. Diagnosis of hereditary or secondary PAP, or a metabolic disorder of surfactant production.
- •2. WLL performed within 3 months prior to baseline.
- •3. Requirement for WLL at screening or baseline.
- •4. GM-CSF treatment within 6 months prior to baseline.
- •5. Treatment with rituximab within 6 months prior to baseline.
- •6. Treatment with plasmapheresis within 6 weeks months prior to baseline.
- •7. Treatment with any investigational medicinal product within 5 half-lives or 3 months (whichever is longer) prior to baseline.
- •8. Previously randomized in this trial.
- •9. History of allergic reactions to GM-CSF or any of the excipients in the nebulizer solution.
- •10. Inflammatory or autoimmune disease of a severity that necessitates significant (e.g. more than 10 mg/day systemic prednisolone) immunosuppression.
- •11. Previous experience of severe and unexplained side-effects during aerosol delivery of any kind of medicinal product.
- •12. History of, or present, myeloproliferative disease or leukemia.
- •13. Apparent pre-existing concurrent pulmonary fibrosis.
- •14. Acute or unstable cardiac or pulmonary disease that may be aggravated by exercise.
- •15. Known active infection (viral, bacterial, fungal, or mycobacterial) that may affect the efficacy evaluation in the trial
- •16. Physical disability or other condition that precludes safe and adequate exercise testing.
- •17. Any other serious medical condition which in the opinion of the Investigator would make the subject unsuitable for the trial.
- •18. Pregnant, planning to become pregnant during the trial, or breastfeeding woman.
研究者
相似试验
已完成
不适用
Clinical trial of fluoride varnish in preventing dental caries of Sjögren’s syndrome patientsISRCTN85164658Research Grants Council of Hong Kong120
尚未招募
3 期
Clinical study for validating the effectiveness of Tendoease tablet in the rehabilitation of tendonitis.CTRI/2024/03/064125Meyer Organics Pvt Ltd
已完成
3 期
Herbal formulation clinical trial for immune supportCTRI/2020/02/023359Botanic Healthcare Pvt Ltd
招募中
3 期
Once-daily inhaled molgramostim nebulizer solution in aPAP.Autoimmune Pulmonary Alveolar Proteinosis(aPAP)JPRN-jRCT2051210036Desai Dhaval40
进行中（未招募）
1 期
A clinical trial where patients with the lung disease autoimmunePulmonary Alveolar Proteinosis will be given the drug molgramostim nebulizer solution by inhalation.Autoimmune Pulmonary Alveolar Proteinosis (aPAP)MedDRA version: 21.1Level: LLTClassification code 10037316Term: Pulmonary alveolar proteinosisSystem Organ Class: 100000004855EUCTR2020-001263-85-DESavara ApS160